Research field (1):
Tumor diagnostics and therapeutics
Research keywords (13):
バイオマーカー
, 細胞内トラフィッキング
, 細胞内シグナル
, 薬剤耐性
, 分子標的薬
, 抗体薬物複合体
, HER2
, Translational research
, Lung Cancer
, Breast Cancer
, Cancer
, Clinical Trial
, Medical Oncology
Research theme for competitive and other funds (13):
2022 - 2025 To investigate mechanisms and a role of folate receptor induction in tumor development
Naoki Miyazaki, Toshiki Iwasaki, Hitomi Sakai, Rurina Watanuki, Yoshinori Tanizawa, Zhihong Cai, Tsutomu Kawaguchi, Junji Tsurutani, Kengo Nagashima. Risk factors for recurrence in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative early breast cancer in Japan: a systematic literature review and meta-analysis. Current medical research and opinion. 2024. 1-11
Masaya Hattori, Naoko Honma, Shigenori Nagai, Kazutaka Narui, Tomoko Shigechi, Yukinori Ozaki, Masayuki Yoshida, Takashi Sakatani, Eiichi Sasaki, Yuko Tanabe, et al. Trastuzumab deruxtecan for human epidermal growth factor receptor 2-low advanced or metastatic breast cancer: recommendations from the Japanese Breast Cancer Society Clinical Practice Guidelines. Breast cancer (Tokyo, Japan). 2024
Takahashi Shunji, Bando Hideaki, Kinoshita Ichiro, Modi Shanu, Tsurutani Junji, Bang Yung-Jue, Sato Yuta, Nakatani Shunsuke, Lee Caleb, Sugihara Masahiro, et al. Trastuzumab deruxtecan in patients with human epidermal growth factor receptor 2-expressing salivary gland carcinoma: a pooled analysis of two phase I studies. Japanese journal of clinical oncology. 2024
Naoki Niikura, Takashi Yamanaka, Hironori Nomura, Kazuhiro Shiraishi, Hiroki Kusama, Mitsugu Yamamoto, Kazuo Matsuura, Kenichi Inoue, Sachiko Takahara, Shosuke Kita, et al. Treatment with trastuzumab deruxtecan in patients with HER2-positive breast cancer and brain metastases and/or leptomeningeal disease (ROSET-BM). NPJ breast cancer. 2023. 9. 1. 82-82
Garrido Charo, Manoogian Melissa, Ghambire Dhiraj, Lucas Shawn, Karnoub Maha, Olson Matthew T, Hicks David G, Tozbikian Gary, Prat Aleix, Ueno Naoto T, et al. Analytical and clinical validation of PATHWAY Anti-HER-2/neu (4B5) antibody to assess HER2-low status for trastuzumab deruxtecan treatment in breast cancer. Virchows Archiv : an international journal of pathology. 2023
Real-world experience with trastuzumab deruxtecan in patients with breast cancer: 6 month-interim analysis of an all-patient postmarketing surveillance in Japan
(SABCS 2023)
Soluble CD163 may be a predictive biomarker of the efficacy of nivolumab plus chemotherapy in patients with HER2-negative metastatic breast cancer (WJOG9917BTR)
(SABCS 2023)
Datopotamab deruxtecan (Dato-DXd) vs chemotherapy in previously-treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer: Primary results from the randomised Phase 3 TROPION-Breast01 trial
(ESMO 2023)
Trastuzumab Deruxtecan (T-DXd) Versus Treatment of Physician’s Choice (TPC) in Patients With HER2-Low Unresectable and/or Metastatic Breast Cancer: Updated Survival Results of the Randomized, Phase 3 DESTINY-Breast04 Study
(ESMO 2023)
Trastuzumab deruxtecan for HER2-positive breast cancer with brain and/or leptomeningeal metastases
(第31回日本乳癌学会学術総会 2023)
2018/08 - 現在 Showa University Advvanced Cancer Translational Research Institute Head, professor
2021/02 - Showa University Hospital The Innovative Center of Translational Research and Clinical Science for Cancer Therapy Professor
2008/01 - 2018/07 Kindai University Faculty of Medicine Department of Medical Oncology Assosiate professor
2006/08 - 2007/12 北九州市立八幡病院 医長
2001/04 - 2007/03 Nagasaki University,Graduate School of Medicine control of infection diseases unit Graduate student
2002/07 - 2006/07 National Institute of Health (USA) National Cancer Institute Research fello
1999/04 - 2001/03 Kindai University Faculty of Medicine Department of Internal Medicine Assistant professor
1995/05 - 1999/03 Nagasaki University Schoolo of Medicine Department of Internal Medicine Assistant professor
Show all
Committee career (12):
2024/02 - 現在 Japanese Society of Medical Oncology Membership committee
2011/04 - 現在 一般社団法人日本乳癌学会 評議員
2011/04 - 現在 公益社団法人日本臨床腫瘍学会 協議員
2024/02 - JSMO director
2023/10 - Monarh study translational research, steering committee
2023/04 - Dato-DXd Global Commercial Breast Cancer Steering Committee
2022/01 - HER2-CLIMB05 steering committee
2021/01 - TROPION-Breast01 steering committee
2019/04 - Safety advisor committee for Enhertu
2019/01 - DESTINY-Breast04 steering committee
2011/04 - JBCS councilor
2011/04 - JSMO councilor
Show all
Awards (8):
2021/06 - Showa University Kamijo Memorial Best Publication Award Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors.
2020/10 - JBCS Best of Breast Cancer Award
2020/10 - Japan Breast Cancer Society Best of Breast Cancer Award Chemotherapy-induced peripheral neuropathy in breast cancer patients treated with eribulin: interim data from a post-marketing observational study
2016/04 - Japanese Society of Clinical Oncology Research Award cfDNA analysis in HER2 positve breast cancer
2015/10 - Kindai Univ. Medical Association Research Award Phase I study of nab-paclitaxel and S-1 in ABC
2013/09 - Lynn Sage Cancer Symposium (Chicago) Travel Award
2009/04 - West Japan Oncology Group Best investigator award
Lynn Sage Breast Cancer Foundation Travel Award Lynn Sage Cancer Symposium (Chicago)
Show all
Association Membership(s) (10):
日本癌治療学会
, 日本乳癌学会
, 日本臨床腫瘍学会
, Japanese Cancer Association
, American Society of Clinical Oncology
, American Association of Cancer Research
, 日本内科学会
, 日本呼吸器学会
, 日本肺癌学会
, 日本気管支鏡学会